Difference between revisions of "Prevalence of cardiac conduction disturbances during carbamazepine treatment: Preliminary data"

From SUDEP Wiki
Jump to navigation Jump to search
(Created page with "''Spina E, Kenneback G, Bergfeldt L, and Tomson T(1987) Prevalence of cardiac conduction disturbances during carbamazepine treatment: Preliminary data. Funct Neurol 2:4 563–...")
 
 
Line 1: Line 1:
−
''Spina E, Kenneback G, Bergfeldt L, and Tomson T(1987) Prevalence of cardiac conduction disturbances during carbamazepine treatment: Preliminary data. Funct Neurol 2:4 563–7.''
+
{{Reference
  
−
'''[https://www.ncbi.nlm.nih.gov/pubmed/?term=Prevalence+of+cardiac+conduction+disturbances+during+carbamazepine+treatment%3A+Preliminary+data Link to Article]'''
+
|reference=
  
−
'''Abstract:''' Twenty-five epileptic patients chronically treated with carbamazepine underwent 24 h electrocardiogram (ECG) monitoring in order to evaluate the prevalence of cardiac conduction abnormalities. Plasma levels of carbamazepine and its metabolite, carbamazepine-10,11-epoxide, were determined by liquid chromatography. Six patients had mild ECG abnormalities. These patients did not differ from the others with respect to plasma concentrations of the drug and its metabolite.
+
Spina E, Kenneback G, Bergfeldt L, and Tomson T(1987) Prevalence of cardiac conduction disturbances during carbamazepine treatment: Preliminary data. Funct Neurol 2:4 563–7.
  
−
=Context=
+
|url=
 +
 
 +
https://www.ncbi.nlm.nih.gov/pubmed/?term=Prevalence+of+cardiac+conduction+disturbances+during+carbamazepine+treatment%3A+Preliminary+data
 +
 
 +
|abstract=
 +
 
 +
Twenty-five epileptic patients chronically treated with carbamazepine underwent 24 h electrocardiogram (ECG) monitoring in order to evaluate the prevalence of cardiac conduction abnormalities. Plasma levels of carbamazepine and its metabolite, carbamazepine-10,11-epoxide, were determined by liquid chromatography. Six patients had mild ECG abnormalities. These patients did not differ from the others with respect to plasma concentrations of the drug and its metabolite.
 +
 
 +
|keywords=
 +
 
 +
 
 +
|context=
  
 
*Early study of effect of CBZ on cardiac function. 25 patients on CBZ underwent 24-hour EKG. Mild EKG abnormalities were found in 6 patients, but blood levels of CBZ or a metabolite were not systematically different from values in the remaining patients.
 
*Early study of effect of CBZ on cardiac function. 25 patients on CBZ underwent 24-hour EKG. Mild EKG abnormalities were found in 6 patients, but blood levels of CBZ or a metabolite were not systematically different from values in the remaining patients.
  
−
=Comments=
+
|comments=
 +
 
 +
 
 +
}}

Latest revision as of 13:51, 17 June 2019


Spina E, Kenneback G, Bergfeldt L, and Tomson T(1987) Prevalence of cardiac conduction disturbances during carbamazepine treatment: Preliminary data. Funct Neurol 2:4 563–7.

Link to Article

Abstract: Twenty-five epileptic patients chronically treated with carbamazepine underwent 24 h electrocardiogram (ECG) monitoring in order to evaluate the prevalence of cardiac conduction abnormalities. Plasma levels of carbamazepine and its metabolite, carbamazepine-10,11-epoxide, were determined by liquid chromatography. Six patients had mild ECG abnormalities. These patients did not differ from the others with respect to plasma concentrations of the drug and its metabolite.

Keywords:

Context

  • Early study of effect of CBZ on cardiac function. 25 patients on CBZ underwent 24-hour EKG. Mild EKG abnormalities were found in 6 patients, but blood levels of CBZ or a metabolite were not systematically different from values in the remaining patients.

Comments

Network Graph

Retrieving data for the network graph...
Retrieved from "https://sudepwiki.pathology.jhmi.edu/index.php?title=Prevalence_of_cardiac_conduction_disturbances_during_carbamazepine_treatment:_Preliminary_data&oldid=1615"